Royalty Pharma Plc (RPRX)
NASDAQ · Healthcare · Biotechnology
Royalty Pharma Plc is a Healthcare company with a market capitalization of $33.14B, a trailing P/E ratio of 30.8, and a dividend yield of 1.55%.
5-Year Price History
Latest Annual Financials · FY ending December 31, 2025
Recent Quarterly Earnings (EPS)
| Quarter | Reported | Actual EPS | Estimate | Surprise |
|---|---|---|---|---|
| Q1 2026 | May 6, 2026 | $1.30 | $1.18 | +10.2% |
| Q4 2025 | February 11, 2026 | $1.47 | $1.33 | +10.5% |
| Q3 2025 | November 5, 2025 | $1.17 | $1.11 | +5.4% |
| Q2 2025 | August 6, 2025 | $1.14 | $1.03 | +10.7% |
| Q1 2025 | May 8, 2025 | $1.06 | $0.95 | +11.6% |
| Q4 2024 | February 11, 2025 | $1.15 | $1.05 | +9.5% |
Short Interest
FINRA-reported short interest for semi-monthly settlement dates, published about nine business days after each settlement. Share counts are adjusted to the current split basis.
| Settlement | Shares Short | % of Shares Out | Days to Cover | Change |
|---|---|---|---|---|
| July 15, 2026 | 12,134,646 | — | 4.4 | -2.5% |
| June 30, 2026 | 12,443,449 | — | 3.0 | +11.8% |
| June 15, 2026 | 11,133,208 | — | 3.0 | -3.9% |
| May 29, 2026 | 11,588,307 | — | 2.5 | -8.6% |
| May 15, 2026 | 12,683,834 | — | 3.3 | -8.2% |
| April 30, 2026 | 13,816,927 | — | 4.4 | +15.0% |
| April 15, 2026 | 12,011,065 | — | 4.4 | +4.3% |
| March 31, 2026 | 11,520,329 | — | 3.3 | -0.5% |
Other Biotechnology Stocks
Frequently Asked Questions
What is Royalty Pharma Plc's market cap?
As of August 13, 2026, Royalty Pharma Plc (RPRX) has a market capitalization of $33.14B.
What is Royalty Pharma Plc's P/E ratio?
Royalty Pharma Plc trades at a trailing price-to-earnings (P/E) ratio of 30.8. Its forward P/E is 47.4.
Does Royalty Pharma Plc pay a dividend?
Yes — Royalty Pharma Plc pays a dividend yielding 1.55%, an annual payout of $0.91 per share.
What sector is RPRX in?
Royalty Pharma Plc is in the Healthcare sector, specifically the Biotechnology industry.
What is Royalty Pharma Plc's short interest?
As of the July 15, 2026 FINRA settlement, 12,134,646 RPRX shares were sold short. Days to cover: 4.4. FINRA publishes short interest twice a month, about nine business days after each settlement date.
What was Royalty Pharma Plc's revenue?
In its latest reported fiscal year (ending December 31, 2025), Royalty Pharma Plc reported revenue of $2.38B and net income of $770.95M.
Ask your own questions about RPRX
Try mrmarket.ai freeData as of August 13, 2026. Figures are sourced from company filings and market data and may be delayed or revised. For informational purposes only — not investment advice.